Wipe Out Kids' Cancer

AutoNation Shifts Drive Pink Campaign Into High Gear to Drive Out Cancer

Retrieved on: 
Thursday, October 12, 2023
Health, NYSE, Memorial Regional Hospital (Florida), Phoenix Children's Hospital, AutoNation, American Cancer Society, Death, Research, Hard Rock Stadium, Breast cancer, NHS foundation trust, Organization, Dolphin, Breast Cancer Research Foundation, Mortality, DRV, Customer, Prostate, Holy Cross Hospital, Hospital, Wipe Out Kids' Cancer, Cancer, BCRF, Prostate cancer, H. Lee Moffitt Cancer Center & Research Institute, Breast, Patient, Cleveland Clinic, Birth control, Pharmaceutical industry

FORT LAUDERDALE, Fla., Oct. 12, 2023 /PRNewswire/ -- As part of an annual tradition, AutoNation, Inc. (NYSE: AN) gathered thousands of Associates coast to coast for Drive Pink (DRV PNK) Across America Day on October 11th.

Key Points: 
  • Associates in AutoNation stores from coast to coast joined in to delivering thousands more bags to local cancer facilities in their communities.
  • AutoNation Associates, Customers and communities have helped DRV PNK raise and donate over $35 million to cancer charities since 2013.
  • Nationally, AutoNation directs its support to BCRF, the American Cancer Society, the National Pediatric Cancer Foundation, and Zero: The End of Prostate Cancer.
  • AutoNation continues to offer its iconic DRV PNK license plate frames to drivers free of charge at all AutoNation stores, to drive awareness.

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma

Retrieved on: 
Monday, April 3, 2023
Army, Neoplasm, Band of Parents, Science, Discovery, MD, Patient, Disease, Children's Hospital of Philadelphia, ALK, Neuroblastoma, Emory University, St. Baldrick's Foundation, Alex's Lemonade Stand Foundation, Pediatrics, Consortium, CHOP, Wipe Out Kids' Cancer, Crizotinib, Research, Lung cancer, Pfizer, MYCN, Anaplastic lymphoma kinase, DOI, Hospital, FDA, NCI, Alvin J. Siteman Cancer Center, Safety, New Approach to Appraisal, Emory University School of Medicine, Winship Cancer Institute, Lipid, Development of the human body, COG, Children's Oncology Group, Weight gain, National Cancer Institute, International Society, Cancer, Adolescence, Band, Ronan (song), Clinical trial, Abdomen, Pharmaceutical industry, Medical imaging, Child, Nature Medicine, Parent

PHILADELPHIA, April 3, 2023 /PRNewswire/ -- In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma. The findings, published today in Nature Medicine, have led to a major amendment in a phase 3 Children's Oncology Group (COG) clinical trial, which has incorporated lorlatinib for newly diagnosed ALK-driven high-risk neuroblastoma, as well as a planned amendment to the European phase 3 trial in collaboration with the International Society of Paediatric Oncology European Neuroblastoma (SIOPEN).

Key Points: 
  • The difficulties we experienced in targeting ALK with crizotinib in neuroblastoma motivated us to find a more potent ALK inhibitor.
  • In the phase 1 NANT trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in pediatric, adolescent, and adult patients with relapsed/refractory ALK-driven neuroblastoma.
  • The researchers noted that younger patients treated with lorlatinib alone – particularly those with amplification of an oncogene called MYCN – had fewer responses compared to older patients.
  • "Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase I trial results," Nature Medicine, April 3, 2023, DOI: 10.1038/s41591-023-02297-5